Mdm2 is a major negative regulator of the tumor suppressor p53 protein, a protein that plays a crucial role in maintaining genome integrity. Inactivation of p53 is the most prevalent defect in human cancers. Inhibitors of the Mdm2–p53 interaction that restore the functional p53 constitute potential nongenotoxic anticancer agents with a novel mode of action. We present here a 2.0 Å resolution structure of the Mdm2 protein with a bound stapled p53 peptide. Such peptides, which are conformationally and proteolytically stabilized with all-hydrocarbon staples, are an emerging class of biologics that are capable of disrupting protein–protein interactions and thus have broad therapeutic potential. The structure represents the first crystal structu...
A recent therapeutic strategy in oncology is based on blocking the protein-protein interaction betwe...
Drug target studies elucidated the core role of protein-protein interaction (PPI) in human disease p...
A recent therapeutic strategy in oncology is based on blocking the protein-protein interaction betwe...
Mdm2 is a major negative regulator of the tumor suppressor p53 protein, a protein that plays a cruci...
Mdm2 is a major negative regulator of the tumor suppressor p53 protein, a protein that plays a cruci...
MDM2 is a negative regulator of p53. The N terminal domain of MDM2 interacts with a helical region o...
MDM2 is a negative regulator of p53. The N terminal domain of MDM2 interacts with a helical region o...
MDM2 is a negative regulator of p53. The N terminal domain of MDM2 interacts with a helical region o...
As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Sm...
As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Sm...
<div><p>As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic ta...
The oncoprotein MDM2 binds to tumor suppressor protein p53 and inhibits its anticancer activity, whi...
Proteins that limit the activity of the tumour suppressor protein p53 are increasingly being targete...
<p>The p53, p63, and p73 proteins belong to the p53 family of transcription factors, which play key ...
Stapling peptides for inhibiting the p53/MDM2 interaction is a promising strategy for developing ant...
A recent therapeutic strategy in oncology is based on blocking the protein-protein interaction betwe...
Drug target studies elucidated the core role of protein-protein interaction (PPI) in human disease p...
A recent therapeutic strategy in oncology is based on blocking the protein-protein interaction betwe...
Mdm2 is a major negative regulator of the tumor suppressor p53 protein, a protein that plays a cruci...
Mdm2 is a major negative regulator of the tumor suppressor p53 protein, a protein that plays a cruci...
MDM2 is a negative regulator of p53. The N terminal domain of MDM2 interacts with a helical region o...
MDM2 is a negative regulator of p53. The N terminal domain of MDM2 interacts with a helical region o...
MDM2 is a negative regulator of p53. The N terminal domain of MDM2 interacts with a helical region o...
As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Sm...
As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Sm...
<div><p>As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic ta...
The oncoprotein MDM2 binds to tumor suppressor protein p53 and inhibits its anticancer activity, whi...
Proteins that limit the activity of the tumour suppressor protein p53 are increasingly being targete...
<p>The p53, p63, and p73 proteins belong to the p53 family of transcription factors, which play key ...
Stapling peptides for inhibiting the p53/MDM2 interaction is a promising strategy for developing ant...
A recent therapeutic strategy in oncology is based on blocking the protein-protein interaction betwe...
Drug target studies elucidated the core role of protein-protein interaction (PPI) in human disease p...
A recent therapeutic strategy in oncology is based on blocking the protein-protein interaction betwe...